| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the Unit of Ophthalmology, Department of Medicine, and the 2 Molecular Genetics and Oncology Group, Clinical Dental Sciences, The University of Liverpool, United Kingdom; 3 The Roy Castle International Centre for Lung Cancer Research, Liverpool, United Kingdom; and the 4 Ocular Oncology Service, St. Paul’s Eye Unit, Royal Liverpool University Hospital, United Kingdom.
PURPOSE. To identify tumor-suppressor loci that may contribute to the pathogenesis of uveal melanoma.
METHODS. Multiplex fluorescence microsatellite assays were performed on 27 uveal melanomas using markers at 3p25-p26, 3p14.2, 9p21-p23, 13q14, 13q12.3-q13, and 17p13, close to or within the von Hippel Lindau (VHL), fragile histidine triad (FHIT), p16/cyclin-dependent kinase inhibitor 2 (CDKN2A), retinoblastoma (RB1), breast cancer 2 (BRCA2), and p53 tumor suppressor loci, respectively. Further markers on chromosomes 3 and 9 were analyzed individually.
RESULTS. Loss of heterozygosity (LOH) was identified in 63% of tumors, most frequently on chromosome 3 (52%), in association with epithelioid cells (P = 0.0002) and microvascular loops (P = 0.0008). In the majority of cases, LOH on chromosome 3 was detected at all informative markers. The second most common alteration was LOH at an RB1 intragenic marker (21% tumors), with retention of a more centromeric 13q marker (near BRCA2). The pattern of LOH on chromosome 9p was consistent with the involvement of a region telomeric to CDKN2A. LOH at TP53 was infrequent.
CONCLUSIONS. In the majority of cases, chromosome 3 LOH involves an entire chromosome homologue, which hampers identification of the relevant suppressor loci. This LOH correlates with the presence of microvascular loops and epithelioid cells, two of the recognized histologic indicators of poor prognosis. Data for chromosomes 13 and 9 support a role for RB1 in the pathogenesis of uveal melanoma but also raise the possibility of the involvement of additional loci close to RB1 and CDKN2A.
This article has been cited by other articles:
|
|
 |
|
  A P Moulin, G Clement, F T Bosman, L Zografos, and J Benhattar Methylation of CpG island promoters in uveal melanoma Br. J. Ophthalmol., February 1, 2008; 92(2): 281 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Ehlers, L. Worley, M. D. Onken, and J. W. Harbour Integrative Genomic Analysis of Aneuploidy in Uveal Melanoma Clin. Cancer Res., January 1, 2008; 14(1): 115 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sandinha, M. Farquharson, I. McKay, and F. Roberts Correlation of Heterogeneity for Chromosome 3 Copy Number with Cell Type in Choroidal Melanoma of Mixed-Cell Type Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5177 - 5180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Sandinha, M. A. Farquharson, I. C. McKay, and F. Roberts Monosomy 3 Predicts Death but Not Time until Death in Choroidal Melanoma Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3497 - 3501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M T Sandinha, M A Farquharson, and F Roberts Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation Br. J. Ophthalmol., December 1, 2004; 88(12): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cohen, N. Goldenberg-Cohen, P. Parrella, I. Chowers, S. L. Merbs, J. Pe'er, and D. Sidransky Lack of BRAF Mutation in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2876 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. M. Scholes, B. E. Damato, J. Nunn, P. Hiscott, I. Grierson, and J. K. Field Monosomy 3 in Uveal Melanoma: Correlation with Clinical and Histologic Predictors of Survival Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1008 - 1011. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
